2023年4月6日

怜悯BioAnalytics -细胞外的先驱vesicle-based液体活检对于癌症的早期发现——宣布,已经完成了一系列4100万美元融资。这种超额认购的融资是由诺瓦利斯LifeSciences Sozo企业的参与,Hatteras Venture Partners, iSelect基金,美国癌症协会的天使和百老汇(一个全风险资本集团)。一轮融资还包括战略投资从Labcorp和力量,除了强大的现有投资者的参与。怜悯BioAnalytics小说怜悯光环平台解锁高临床敏感性和特异性通过同时检测多种癌症相关的生物标记物表面硝唑个人tumor-derived细胞外囊泡。和丰富的细胞外囊泡在循环使摆布光环测试运行在一个非常小的体积与一个简单的pcr读出血清或血浆。融资所得将用于推进发展和商业化的仁慈光环测试高危肺癌筛查,该公司的主要临床表现。和肺癌是癌症死亡的主要原因在全球范围内,有超过350的美国人每天死于肺癌。目前有超过1400万的美国人推荐年度肺癌筛查,但不到6%的人有资格参与成像筛查项目。这样一个易于管理的血检怜悯光环可以帮助解决这一挑战。这一轮资金还将用于推进临床项目额外的迹象,包括卵巢癌,80%的病例诊断在三期或四期可怜的长期生存。 And Mercy plans to leverage its Mercy Halo liquid biopsy platform technology to develop a broad portfolio of tests for the early detection of cancer. The data presented last year at the annual meetings of the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR), and at the Early Detection of Cancer Conference (EDCC), demonstrated promising preliminary performance for Mercy Halo assays in detecting Stage I and II lung cancer and ovarian cancer. And the company is currently planning and executing studies to validate assay performance in larger independent patient cohorts in these and other indications. Mercy will be presenting additional new data at the upcoming AACR conference in Orlando, Florida this month, and at the upcoming International Society for Extracellular Vesicles (ISEV) annual meeting in Seattle, Washington in May. KEY QUOTES: “Cancer remains a leading cause of death globally, and liquid biopsy-based screening represents a meaningful opportunity to address barriers that contribute to disparities in early cancer detection, including in medically underserved populations. We believe the Mercy Halo testing platform is uniquely capable of delivering high-performing, broadly accessible cancer screening across all communities. A simple, inexpensive blood-based screening test could be a vital new tool to significantly increase patient engagement in lung cancer screening, creating the opportunity to save lives through early detection. We are grateful for the support from Novalis, the American Cancer Society BrightEdge and others, and are humbled by their belief in our mission to relieve suffering and save lives through our unique Mercy Halo technology.” — Mercy BioAnalytics CEO Dawn Mattoon, PhD “Liquid biopsy is an important advance in clinical testing that has not yet been fully realized. Mercy is taking a unique approach designed to address the challenges that have plagued early cancer detection liquid biopsy tests that seek to measure tumor-derived DNA. We have been impressed with Mercy’s early clinical data, their relentless focus on scientific rigor, and thoughtful approach to commercialization. We are excited to partner with the company to further validate their Mercy Halo test portfolio across the most challenging cancers we face.” — Paul Meister, Partner at Novalis LifeSciences, and member of Mercy’s Board of Directors Trending on Pulse 2.0